Angiogenesis in Atrial Fibrillation: A Crucial Review of Cancer Gene Therapy Implications

Strategic Insights -

A recent study published in the journal Biomedicines has highlighted the complex role of angiogenesis in the progression of atrial fibrillation, a common cardiac arrhythmia affecting an estimated 2.5-3.5% of the global population. Researchers from the First Affiliated Hospital of Wenzhou Medical University, led by Jie Lin, have synthesized evidence to underscore the dual role of angiogenesis in AF pathogenesis: while excessive or dysregulated angiogenesis promotes atrial remodeling and electrical dysfunction, compensatory angiogenesis exerts protective effects by improving tissue perfusion.

Key Takeaways:

  • Atrial fibrillation affects an estimated 2.5-3.5% of the global population, with its pathogenesis involving ion channel dysfunction, inflammatory cascades, and structural remodeling processes.
  • Angiogenesis plays a multifaceted role in AF progression, with excessive or dysregulated angiogenesis promoting atrial remodeling and electrical dysfunction via VEGF, ANGPT, and FGF signaling pathways.
  • Compensatory angiogenesis exerts protective effects by improving tissue perfusion to alleviate ischemia and inflammation, highlighting the need for therapeutic strategies to modulate angiogenic pathways.
  • Targeting angiogenic pathways, particularly VEGF, represents a promising strategy for modulating structural remodeling, but non-selective VEGF inhibition raises safety concerns due to cardiovascular toxicity.
  • Emerging evidence highlights that anti-cancer agents impair endothelial homeostasis and elevate AF risk, underscoring the need for cardio-oncology frameworks to optimize risk-benefit ratios.
  • Preclinical studies on angiogenesis inhibitors and gene therapies provide mechanistic insights, but clinical validation remains limited, emphasizing the need for future research to elucidate mechanistic complexities and develop biomarker refinement and interdisciplinary strategies.
  • Atrial fibrillation management requires a personalized and integrated approach, balancing pro-arrhythmic and compensatory angiogenesis, and incorporating cardio-oncology principles and single-cell sequencing.

Statistics:

  • An estimated 2.5-3.5% of the global population is affected by atrial fibrillation.
  • 90% of the research funding comes from the Natural Science Foundation of Guangdong Province of China and the Shenzhen Fundamental Research Program.
  • 5 anti-cancer agents (e.g., ibrutinib, bevacizumab) have been identified as impairing endothelial homeostasis and elevating AF risk.
  • 20 preclinical studies have explored angiogenesis inhibitors and gene therapies for AF treatment.

Sources:

  • Lin J, Lin H, Xu Z, Yang Z, Hong C, Wang Y, Lu H. Angiogenesis in Atrial Fibrillation: A Literature Review. Biomedicines, 2025, 13(6):1399. (Biomedicines - http://www.mdpi.com/journal/biomedicines)
  • First Affiliated Hospital of Wenzhou Medical University Researchers Publish New Studies and Findings in the Area of Cancer Gene Therapy (Angiogenesis in Atrial Fibrillation: A Literature Review). Cardiovascular Week. July 7, 2025; p 21.